
WHAT IS CLAIMED

1. A compound comprising a structure of Formula (**I**), or an enantiomer, diastereomer or pharmaceutically accepted salt, hydrate, solvate, prodrug or complex thereof:



(**I**)

wherein:

A is selected from a group consisting of SO_2 and CO;

R^1 is selected from a group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, and optionally substituted benzyl, optionally substituted 3-7 membered cycloheteroalkyl, optionally substituted C_{2-8} alkenyl, optionally substituted C_{2-8} alkynyl, optionally substituted C_{1-6} alkoxy, optionally substituted amine, optionally substituted amidine, optionally substituted carboxyamine, optionally substituted carboxy-C_{1-6}-alkoxide, -SO_2-C_{1-6}alkyl, optionally substituted heterocyclic, or optionally substituted heteroaryl;

R^2 is selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{3-7} cycloalkyl, and optionally substituted heterocyclic; or

R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocycle with 3 to 10 atoms; and

R^3 is selected from a group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, optionally substituted alkylheteroaryl, and optionally substituted C_{1-6} linear alkyl;

R^4 is selected from a group consisting of hydrogen and optionally substituted C_{1-6} linear alkyl;

R^5 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano and $N(R^9)_2$;

R^6 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$; or

R^4 and R^6 are taken together with the atoms to which they are bound to form an optionally substituted carbocyclic or heterocyclic ring with 5 to 6 atoms, optionally containing a carbonyl, optionally containing two carbonyls; and

R^7 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, OR^9, cyano and $N(R^9)_2$;


R^8 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, OR^9, cyano and $N(R^9)_2$; or


R^2 and R^8 are taken together with the atoms to which they are bound to form an optionally substituted carbocyclic or heterocyclic ring with 5 to 6 atoms; and

R^9 is independently at each occurrence selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;


provided that when A is SO_2; R^4 and R^6 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and R^2 and R^8 taken together with the atoms to which they are bound do not to form an optionally substituted ring, then none of the following (a) through (d) apply:


(a) R^3 is an optionally substituted phenyl and R^1 or R^2, either individually or when taken together, contain a hydroxyl group; or

(b) R^3 is an optionally substituted alkyl or phenyl, and $N(R^1)(R^2)$ is an optionally substituted piperazine or 




(c) R^3 is optionally substituted alkyl, aryl, or alkaryl and $N(R^1)(R^2)$ is








(d) either R^3 or R^4 is an unsubstituted or monosubstituted aryl, or an unsubstituted or monosubstituted aralkyl, or unsubstituted or monosubstituted heteroaryl and R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocyclic ring structure with 6 to 12 atoms; or

provided that the compound is not 3-{[(dicyclopropylmethyl)amino]sulfonyl}-N-(4-isopropoxyphenyl)benzamide; or 3-({[2-(1H-benzimidazol-2-yl)propyl]amino}sulfonyl)-N-(4-isopropoxyphenyl)benzamide; or 3-[(cyclohexylamino)sulfonyl]-N-(4-isopropylphenyl)benzamide; or 3-(anilinosulfonyl)-N-(4-isopropylphenyl)benzamide; or 5-{[(3-{[(4-methoxyphenyl)amino]carbonyl}phenyl)sulfonyl]amino}pentanoic acid; or 3-[(*tert*-butylamino)sulfonyl]-N-(4-methoxyphenyl)benzamide; or (3S)-1-[(3-{[(5-isopropoxypyridin-2-yl)amino]carbonyl}phenyl)sulfonyl]piperidine-3-carboxamide; or (3R)-1-[(3-{[(5-isopropoxypyridin-2-yl)amino]carbonyl}phenyl)sulfonyl]piperidine-3-carboxamide; or 3-(piperidin-1-ylsulfonyl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide; or N-(5-bromo-3-methoxypyridin-2-yl)-3-(piperidin-1-ylsulfonyl)benzamide; or N-(3-methoxy-5-phenylpyridin-2-yl)-3-(pyrrolidin-1-ylsulfonyl)benzamide; or N-(3-methoxy-5-phenoxypyridin-2-yl)-3-(pyrrolidin-1-ylsulfonyl)benzamide; or N-[3-methoxy-5-(phenylthio)pyridin-2-yl]-3-(pyrrolidin-1-ylsulfonyl)benzamide; or N-(5-ethyl-3-methoxypyridin-2-yl)-3-(piperidin-1-ylsulfonyl)benzamide; or N-(3-methoxy-5-vinylpyridin-2-yl)-3-(piperidin-1-ylsulfonyl)benzamide; or



;


;


;


(XXVII)

; or


(XXVIII)


.

2. The compound of claim 1 wherein:




R^4 and R^6 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and

R^2 and R^8 taken together with the atoms to which they are bound do not to form an optionally substituted ring;

thereby providing compounds having formula:



3. The compound of claim 1, the compound comprising one of the following structures:


,

, or


wherein, as appropriate:

R^4 and R^6 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and

R^2 and R^8 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and

wherein z and f are independently is 0 or 1, and y is independently 0, 1, or 2.

4. The compound of claim 1, wherein A is SO_2.

5. The compound of claim 1, wherein A is CO.

6. The compound of claim 1, wherein

R^3 is selected from a group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl; and


where present, R^4 is hydrogen.

7. The compound of claim 6, wherein

R^3 is selected from a group consisting of optionally substituted phenyl, optionally substituted benzyl, optionally substituted benzoisoxazolyl,optionally substituted benzooxazolyl, optionally substituted furyl, optionally substituted imidazolyl, optionally substituted indoyl, optionally substituted isoxazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted pyrazolyl, optionally substituted pyridin-2-on-yl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally

substituted quinolinyl, optionally substituted thiazolyl optionally substituted thienyl, and optionally substituted methylpyridyl.

8. The compound of claim 7, wherein R^3 is



wherein

R_S is independently at each occurrence bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl, -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety; and x is 0, 1, 2, or 3.


x is 0, 1, 2, or 3; and


where present, R^4 is hydrogen.

9. The compound of claim 7, wherein the optional substitution of R^3 comprises at least one halo or C_{1-6} alkyl.

10. The compound of claim 9, wherein the optional substitution of R^3 comprises at least one halo.

11. The compound of claim 1, wherein R^3 is






12. The compound of claim 1, wherein

R^5, and R^7 are each independently at each occurrence H or F; and

R^6 and R^8 are each independently at each occurrence hydrogen, chloro, fluoro, or C_{1-3} alkyl, or C_{1-3}alkoxy..

13. The compound of claim 1, wherein

R^3 is  ; and

where present, R^4 is hydrogen.


14. The compound of claim 1, wherein


R^5, R^7, and R^8 are each H; and


R^6 is hydrogen, chloro, fluoro, or methoxy.

15. The compound of claim 1, wherein,

R^1 is methyl, methoxy, ethyl, ethoxy, n-propyl, n-propoxy, isopropyl, isopropoxy, n-butyl, n-butoxy, sec-butyl, sec-butoxy, tert-butyl, tert-butoxy, optionally substituted phenyl, optionally substituted benzyl, optionally substituted benzoisoxazolyl,optionally substituted benzooxazolyl, optionally substituted furyl, optionally substituted imidazolyl, optionally substituted indoyl, optionally substituted isoxazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted pyrazolyl, optionally substituted pyridin-2-on-yl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted quinolinyl, optionally substituted thiazolyl optionally substituted thienyl, and optionally substituted methylpyridyl,





O
N
F
NH2
OH
O
NHBoc
CH3
CF3
OH
OMe
CN
COOH



, or ; and

where present, R^2 is H.

16. The compound of claim 15, wherein R^1 is isopropyl, t-butyl,





and, where present, R^2 is H.

17. The compound of claim 1, with the proviso that the -N(R^1)(R^2) moiety does not contain hydroxyl.


18. The compound of claim 1, with the proviso that R^1 is not cyclopentane.

19. The compound of claim 1, wherein







20. The compound of claim 1, comprising a structure



wherein R^1 is





and R^3 is




wherein

R_S is independently at each occurrence bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl, -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety; and x is 0, 1, 2, or 3.


21. The compound of claim 20, comprising a structure





wherein R^1 is




and R^3 is







22. The compound of claim 1, comprising a structure



wherein R^1 is isopropyl, t-butyl,




23. The compound of claim 3, the compound comprising a structure:




wherein y is 0, 1, or 2.

24. The compound of claim 23, wherein

R^1 is isopropyl, t-butyl,




R^3 is  ;

R^4, R^5, and R^7 are H; and

R^6 is H or F.


25. The compound of claim 3, the compound comprising a structure:




wherein z is 0 or 1.

26. The compound of claim 25, wherein

R^1 is isopropyl, tert-butyl,




R^3 is  ;

R^5, and R^7 are H; and

R^8 is H or F.


27. The compound of claim 3, the compound comprising a structure:




wherein f is 0 or 1.

28. The compound of claim 27, wherein

R^1 is isopropyl, tert butyl,




R^2 is H;

R^3 is ;

R^5, and R^7 are H; and

R^8 is H or F.


29. The compound of claim 3, the compound comprising a structure:




wherein g is 0 or 1.

30. The compound of claim 29, wherein

R^1 is isopropyl, tert-butyl,




R^2 is H;

R^3 is ;

R^5, and R^7 are H; and

R^8 is H or F.


31. The compound of claim 3, the compound comprising a structure:




wherein h is 0 or 1.

32. The compound of claim 31, wherein

R^1 is isopropyl, *tert*-butyl,




R^2 is H;

R^3 is ;

R^5, and R^7 are H; and


R^8 is H or F.

33. The compound of claim 1, the compound comprising a structure of any one of:




(XXIX)

,




(XXX)

,




(XXXI)

,




(XXXII)

,




(XXXIII)

,




(XXXIV)

,



(XXXV)


,




(XXXVI)

, wherein

R^1 is isopropyl, t-butyl,




,



, , , , or ; and


R^2 is H.

34. The compound of claim 1, the compound comprising a structure of Formula (**XXII**):




(XXII)

35. The compound of claim 1, the compound comprising a structure of Formula (**XXIII**):




(XXIII)

36. The compound of claim 1, the compound comprising a structure of Formula (**XXIV**):




(XXIV)

37. The compound of claim 1, the compound comprising a structure of Formula (**XXV**):




(XXV)

38. A compound comprising a structure of Formula (**III**) or Formula (**VIII**), or an enantiomer, diastereomer or pharmaceutically accepted salt thereof:



(**III**)



(**VIII**)

wherein:

R^1 is selected from a group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, and optionally substituted benzyl;

R^2 is selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{3-7} cycloalkyl, and optionally substituted heterocyclic; or

R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocycle with 3 to 10 atoms; and

R^5 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^6 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^7 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^8 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$; or


R^2 and R^8 are taken together with the atoms to which they are bound to form an optionally substituted ring with 5 to 6 atoms; and

R^9 is independently at each occurrence selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;

R^{10} is selected from a group consisting of optionally substituted aryl and optionally substituted heteroaryl; and

n is 0 or 1.

39. A compound comprising a structure of Formula (**XI**), or an enantiomer, diastereomer or pharmaceutically accepted salt thereof:



(XI)

wherein:

R^1 is selected from a group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, and optionally substituted benzyl;

R^5 is selected from a group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, optionally substituted alkylheteroaryl; and optionally substituted C_{1-6} linear alkyl;

R^4 is selected from a group consisting of hydrogen and optionally substituted C_{1-6} linear alkyl;

R^5 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^6 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$; or

R^4 and R^6 are taken together with the atoms to which they are bound to form an optionally substituted carbocyclic or heterocyclic ring with 5 to 6 atoms, optionally containing a carbonyl, optionally containing two carbonyls;

R^7 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;


R^8 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^9 is independently at each occurrence selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and

R^{11} is selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, and optionally substituted C_{3-7} cycloalkyl.

40. The compound of claim 39, wherein A is SO_2.


41. The compound of claim 39, the compound comprising a structure of Formula (**XIII**):



(XIII)

wherein k is 0 or 1.

42. The compound of claim 39, the compound comprising a structure of Formula (**XIV**),




(XIV)

where j is 0 or 1.

43. The compound of claim 39, wherein A is carbonyl, CO.


44. The compound of claim 39, the compound comprising a structure of Formula (**XVI**):



(XVI)

wherein r is 0 or 1.


45. The compound of claim 39, the compound comprising a structure of Formula (**XVII**),



(XVII)


wherein t is 0 or 1.

46. The compound of claim 39, the compound comprising a structure of Formulae XXXXVII:




(XXXXVII)


47. The compound of claim 39, the compound comprising a structure of



or





wherein R^1 is isopropyl, t-butyl,



, or


R^3 is







R_S is independently at each occurrence bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl, -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety; and x is 0, 1, 2, or 3.


48. The compound of claim 47, wherein R^1 is




and R^3 is







49. A compound comprising a structure of Formula (**XVIII**), or an enantiomer, diastereomer or pharmaceutically accepted salt thereof:



(XVIII)

wherein:

A is selected from a group consisting of SO_2 and CO;

R^1 is selected from a group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, and optionally substituted benzyl;

R^5 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9 , cyano, and $N(R^9)_2$;

R^6 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^7 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^8 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} *haloalkyl*, OR^9, *cyano*, *and* $N(R^9)_2$; or

R^9 is independently at each occurrence selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;


R^{12} is selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, and optionally substituted C_{3-7} cycloalkyl; and

R^{13} is selected from a group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl.

50. The compound of claim 49, wherein A is SO_2.

51. The compound of claim 49, wherein A is carbonyl, CO.

52. A compound comprising a structure of Formula (**XXI**), or an enantiomer, diastereomer or pharmaceutically accepted salt thereof:



(XXI)

wherein:

R^1 is selected from a group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, and optionally substituted benzyl;

R^2 is selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{3-7} cycloalkyl, and optionally substituted heterocyclic; or

R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocycle with 3 to 10 atoms;

R^5 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^6 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^7 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^8 is selected from a group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$; or


R^2 and R^8 are taken together with the atoms to which they are bound to form an optionally substituted ring with 5 to 6 atoms;

R^9 is independently at each occurrence selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl.

R^{12} is selected from a group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, and optionally substituted C_{3-7} cycloalkyl; and


R^{13} is selected from a group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl.

53. The compound of claim 52, the compound comprising a structure of Formulae XXXXVIII:




(XXXXVIII)


54. The compound of claim 52, the compound comprising a structure of




or




wherein R^1 is






, or


R^{13} is







R_S is independently at each occurrence bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl , -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety; and x is 0, 1, 2, or 3.


55. The compound of claim 54, wherein R^1 is




and R^{13} is







or


.

56. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

57. An effective amount of at least one compound of claim 1 for use in treating a disease that involves pregenomic RNA encapsidation in a patient in need of such treatment.

58. The compound of claim 57, wherein the disease that involves pregenomic RNA encapsidation is a Hepatitis B virus infection.

59. An effective amount of at least one compound of claim 1 for use in treating a Hepatitis B viral infection in a patient in need of such treatment.

60. The compound of claim 59, wherein the treatment controls or ameliorates a condition associated with liver disease, including cirrhosis and hepatocellular carcinoma.

61. A compound of claim 1 for use in repressing viral replication, morphogenesis, or both replication and morphogenesis in a patient in need thereof.

62. Use of an effective amount of at least one compound of claim 1 in the manufacture of a medicament for treating a disease that involves pregenomic RNA encapsidation in a patient in need of such treatment.

63. The use of claim 62, wherein the disease that involves pregenomic RNA encapsidation is a Hepatitis B virus infection.


64. Use of an effective amount of at least one compound of claim 1 in the manufacture of a medicament for treating a Hepatitis B viral infection in a patient in need of such treatment.

65. The use of claim 64, wherein the treatment controls or ameliorates a condition associated with liver disease, including cirrhosis and hepatocellular carcinoma.

66. Use of a compound of claim 1 in the manufacture of a medicament for repressing viral replication, morphogenesis, or both replication and morphogenesis in a patient in need thereof.

Claims

1. A compound comprising the structure of Formula (**I**), or an enantiomer, diastereomer, or pharmaceutically accepted salt, hydrate, or solvate thereof:



(**I**)

wherein in (**I**):

A is selected from the group consisting of SO_2 and CO;

R^1 is selected from the group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted benzyl, optionally substituted 3-7 membered cycloheteroalkyl, optionally substituted C_{2-8} alkenyl, optionally substituted C_{2-8} alkynyl, optionally substituted C_{1-6} alkoxy, and optionally substituted heterocyclic;

R^2 is selected from the group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{3-7} cycloalkyl, and optionally substituted heterocyclic; or

R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocycle with 3 to 10 atoms; and

R^3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;

R^4 is selected from the group consisting of hydrogen and optionally substituted C_{1-6} linear alkyl;

R^5 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano and $N(R^9)_2$;

R^6 and R^8 are each selected independently at each occurrence from the group consisting of hydrogen, chloro, fluoro, C_{1-3} alkyl, and C_{1-3} alkoxy, wherein at least one selected from the group consisting of R^6 and R^8 is not hydrogen; or

R^4 and R^6 are taken together with the atoms to which they are bound to form an optionally substituted heterocyclic ring with 5 to 6 atoms, optionally containing one or two carbonyls; or





















R^2 and R^8 are taken together with the atoms to which they are bound to form an optionally substituted heterocyclic ring with 5 to 6 atoms;


R^7 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, OR^9, cyano and $N(R^9)_2$;

R^9 is independently at each occurrence selected from the group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;


provided that when A is SO_2; R^4 and R^6 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and R^2 and R^8 taken together with the atoms to which they are bound do not to form an optionally substituted ring, then the compound is not selected from any of groups (a) through (e):

(a) R^3 is optionally substituted phenyl; and R^1 or R^2, either individually or when taken together, contain a hydroxyl group; or

(b) R^3 is optionally substituted phenyl; and $N(R^1)(R^2)$ is selected from the group consisting of optionally substituted piperazine, , , , , , , , , , , , , , , , , , , , , , , , 



(c) R^3 is optionally substituted aryl, and $N(R^1)(R^2)$ is selected from the group consisting of:



(d) R^3 is unsubstituted or monosubstituted aryl, or unsubstituted or monosubstituted heteroaryl; and R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocyclic ring structure with 6 to 12 atoms; or

(e) a compound selected from the group consisting of:

3-{[(dicyclopropylmethyl)amino]sulfonyl}-N-(4-isopropoxyphenyl)benzamide;

3-({[2-(1H-benzimidazol-2-yl)propyl]amino}sulfonyl)-N-(4-isopropoxyphenyl) benzamide;

3-[(cyclohexylamino)sulfonyl]-N-(4-isopropylphenyl)benzamide;

3-(anilinosulfonyl)-N-(4-isopropylphenyl)benzamide;

5-{[(3-{[(4-methoxyphenyl)amino]carbonyl}phenyl)sulfonyl]amino}pentanoic acid;

3-[(*tert*-butylamino)sulfonyl]-N-(4-methoxyphenyl)benzamide;

(3S)-1-[(3-{[(5-isopropoxypyridin-2-yl)amino]carbonyl}phenyl)sulfonyl] piperidine-3-carboxamide;

(3R)-1-[(3-{[(5-isopropoxypyridin-2-yl)amino]carbonyl}phenyl)sulfonyl] piperidine-3-carboxamide;

3-(piperidin-1-ylsulfonyl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide;

N-(5-bromo-3-methoxypyridin-2-yl)-3-(piperidin-1-ylsulfonyl)benzamide;



N-(3-methoxy-5-phenylpyridin-2-yl)-3-(pyrrolidin-1-ylsulfonyl)benzamide;



N-(3-methoxy-5-phenoxypyridin-2-yl)-3-(pyrrolidin-1-ylsulfonyl)benzamide;

N-[3-methoxy-5-(phenylthio)pyridin-2-yl]-3-(pyrrolidin-1-ylsulfonyl)benzamide;

N-(5-ethyl-3-methoxypyridin-2-yl)-3-(piperidin-1-ylsulfonyl)benzamide;

N-(3-methoxy-5-vinylpyridin-2-yl)-3-(piperidin-1-ylsulfonyl)benzamide;


; 
;



; and 
.

2. The compound of claim 1 wherein:




R^4 and R^6 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and

R^2 and R^8 taken together with the atoms to which they are bound do not to form an optionally substituted ring;

thereby providing compounds having formula:


.

3. The compound of claim 1, the compound comprising one of the following structures:

(A) **(B)** **(C)**

wherein:

in **(A)** R^4 and R^6 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and

in **(B)** and **(C)** R^2 and R^8 taken together with the atoms to which they are bound do not to form an optionally substituted ring; and

wherein z and f are independently 0 or 1, and y is independently 0 or 1.


4. The compound-of claim 1, wherein A is SO_2.


5. The compound-of claim 1, wherein A is CO.

6. The compound of claim 1, wherein

R^3 is selected from a group consisting of optionally substituted phenyl, optionally substituted benzoisoxazolyl, optionally substituted benzooxazolyl, optionally substituted furyl, optionally substituted imidazolyl, optionally substituted indoyl, optionally substituted isoxazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted pyrazolyl, optionally substituted pyridin-2-on-yl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted quinolinyl, optionally substituted thiazolyl optionally substituted thienyl.

7. The compound of claim 6, wherein R^3 is





wherein

R_S is independently at each occurrence selected from the group consisting of bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl, and -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety;


x is 0, 1, 2, or 3; and


where present, R^4 is hydrogen.

8. The compound of claim 6, wherein the optional substitution of R^3 comprises at least one halo or C_{1-6} alkyl.

9. The compound of claim 8, wherein the optional substitution of R^3 comprises at least one halo.

10. The compound of claim 1, wherein R^3 is






11. The compound of claim 1, wherein

R^5 and R^7 are independently at each occurrence H or F.

12. The compound of claim 1, wherein

R^3 is  ; and

where present, R^4 is hydrogen.


13. The compound of claim 1, wherein


R^5, R^7, and R^8 are each H; and

R^6 is chloro, fluoro, or methoxy.

14. The compound of claim 1, wherein,


R^1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, optionally substituted benzyl, optionally substituted methylpyridyl,




F
F
F
F
N
N
F
F
N
N
O
OH
O
NH2
NHBoc
CH3
CF3
OH
OMe
CN
COOH
CH3
CF3
OH
OMe
CN
COOH
CH3
CF3
OH
OMe
CN
COOH
CH3
CF3
OH
OMe
CN
COOH
O
O
O
O
O
N
N
N
N
, or
; and

where present, R^2 is H.

15. The compound of claim 14, wherein R^1 is isopropyl, t-butyl,




, or


, and,

where present, R^2 is H.

16. The compound of claim 1, with the proviso that R^1 is not cyclopentane


17. The compound of claim 1, wherein 

is




, or .


18. The compound of claim 1, comprising a structure



wherein R^1 is





and R^3 is




wherein

R_S is independently at each occurrence selected from the group consisting of bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl, and -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety; and x is 0, 1, 2, or 3.


19. The compound of claim 18, comprising a structure



or

,

wherein R^1 is




and R^3 is







20. The compound of claim 1, comprising a structure



wherein R^1 is isopropyl, t-butyl,




21. The compound of claim 3, the compound comprising a structure:




wherein y is 0 or 1.

22. The compound of claim 21, wherein

R^1 is isopropyl, t-butyl,






R^3 is ;

R^4, R^5, and R^7 are H; and

R^6 is H or F.

23. The compound of claim 3, the compound comprising a structure:




,


wherein z is 0 or 1.

24. The compound of claim 23, wherein

R^1 is isopropyl, tert-butyl,




;

R^3 is ;

R^5, and R^7 are H; and

R^8 is H or F.


25. The compound of claim 3, the compound comprising a structure:

,


wherein f is 0 or 1.

26. The compound of claim 25, wherein

R^1 is isopropyl, tert butyl,




R^2 is H;

R^3 is ;

R^5, and R^7 are H; and

R^8 is H or F.


27. The compound of claim 3, the compound comprising a structure:



wherein g is 0 or 1.


28. The compound of claim 27, wherein

R^1 is isopropyl, tert-butyl,



;


R^2 is H;

R^3 is ;

R^5, and R^7 are H; and

R^8 is H or F.


29. The compound of claim 3, the compound comprising a structure:




wherein h is 0 or 1.

30. The compound of claim 29, wherein

R^1 is isopropyl, *tert*-butyl,




R^2 is H;


R^3 is ;

R^5, and R^7 are H; and


R^8 is H or F.


31. The compound of claim 1, which is selected from the group consisting of:




(XXIX), 


(XXX),




(XXXI), 


(XXXII),



(XXXIII), 


(XXXIV),



(XXXV), and 


(XXXVI), wherein

R^1 is isopropyl, t-butyl,



R^2 is H.


32. The compound of claim 1, the compound comprising the structure of Formula (**XXII**):



(**XXII**)

.


33. The compound of claim 1, the compound comprising the structure of Formula (**XXIV**):



(**XXIV**)

.

34. A compound comprising the structure of Formula (**XXI**), or an enantiomer, diastereomer or pharmaceutically accepted salt thereof:



(**XXI**)

wherein:

R^1 is selected from the group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, and optionally substituted benzyl;

R^2 is selected from the group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{3-7} cycloalkyl, and optionally substituted heterocyclic; or

R^1 and R^2 are taken together with the atoms to which they are bound to form an optionally substituted heterocycle with 3 to 10 atoms;

R^5 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^6 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^7 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$;

R^8 is selected from the group consisting of hydrogen, halogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{1-6} haloalkyl, OR^9, cyano, and $N(R^9)_2$; or


R^2 and R^8 are taken together with the atoms to which they are bound to form an optionally substituted ring with 5 to 6 atoms;

R^9 is independently at each occurrence selected from the group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, optionally substituted C_{3-7} cycloalkyl, optionally substituted aryl, optionally substituted benzyl, optionally substituted heterocyclyl, and optionally substituted heteroaryl.

R^{12} is selected from the group consisting of hydrogen, optionally substituted C_{1-6} linear alkyl, optionally substituted C_{1-6} branched alkyl, and optionally substituted C_{3-7} cycloalkyl; and



R^{13} is selected from the group consisting of optionally substituted aryl, optionally substituted benzyl, optionally substituted alkylaryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl.

35. The compound of claim 34, the compound comprising a structure of Formula **(XXXXVIII)**:




(XXXXVIII)


36. The compound of claim 34, the compound comprising the structure of


or


wherein R^1 is




R^{13} is





R_S is independently at each occurrence selected from the group consisting of bromo, chloro, fluoro, cyano, hydroxyl, optionally fluorinated C_{1-6} alkyl, and -O-(C_{1-6} alkyl), or when two are taken form a fused cyclic or heterocyclic moiety; and x is 0, 1, 2, or 3.

37. The compound of claim 36, wherein R^1 is



and R^{13} is





38. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient

39. An effective amount of at least one compound of claim 1 for use in treating a Hepatitis B virus infection in a patient in need of such treatment.

40. Use of an effective amount of at least one compound of claim 1 in the manufacture of a medicament for treating cirrhosis in a patient in need of such treatment.

41. Use of an effective amount of at least one compound of claim 1 in the manufacture of a medicament for treating hepatocellular carcinoma in a patient in need of such treatment.